Zura Bio Limited Class A (ZURA)

Over the past six months, Zura Bio reported its First Quarter and Full Year financial results, including a net loss for the quarter and advancements in its Phase 2 studies. They also announced inducement grants, participation in investor conferences, and the closing of a $144 million public offering. The stock price has fluctuated, with a recent decrease but a significant gain over the past 12 months. The public offering in February 2026 generated gross proceeds of approximately $144 million, strengthening the company's balance sheet and extending its cash runway through at least the end of 2028.

As a clinical-stage biotechnology company, Zura Bio Ltd.'s products are currently in development and not yet commercialized. Therefore, there is no information available regarding demand seasonality for its products or services.

Zura Bio Ltd. is a clinical-stage immunology company focused on developing dual-pathway antibodies for autoimmune and inflammatory diseases. Their pipeline includes Tibulizumab (ZB-106), a bispecific antibody in Phase 2 trials for hidradenitis suppurativa and systemic sclerosis; Crebankitug (ZB-168), a monoclonal antibody targeting IL-7R that has completed Phase 1/1b studies; and Torudokimab (ZB-880), a monoclonal antibody neutralizing IL-33, also having completed Phase 1/1b studies.

Zura Bio Ltd. is headquartered in Henderson, Nevada, United States, and focuses on developing medicines for autoimmune and inflammatory disorders in the United States. While its shareholder base is international, its primary operational and development focus is within the United States.

Information explicitly detailing Zura Bio Ltd.'s brand reputation is not readily available. Analyst sentiment varies, with some analysts issuing a "Strong Buy" rating and others a "Sell (D-)" rating. The company actively maintains transparency and engages with the investment community through consistent reporting and participation in investor conferences.

Zura Bio Ltd.'s ownership is a mix of institutional, retail, and individual investors. Institutional investors own approximately 0.21% to 2.44% of the stock, insiders own 12.17%, and public companies and individual investors own 85.39%. Major institutional owners include Suvretta Capital Management, VR Adviser, JPMorgan Chase & Co, and Pfizer Inc, among others. Key individual and insider owners include Ai Biotechnology Llc, Someit Sidhu, Amit Munshi, and Kim Davis.